Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,336.28% | 2,873.41% | -- | -- | 158.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,336.28% | 2,873.41% | -- | -- | 158.40% |
| Cost of Revenue | 24.54% | 31.53% | 29.39% | 46.13% | 37.63% |
| Gross Profit | 5.53% | -18.01% | -20.13% | -45.90% | -36.80% |
| SG&A Expenses | 15.51% | 43.08% | 90.56% | 101.86% | 100.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.08% | 35.20% | 47.58% | 62.57% | 56.46% |
| Operating Income | -2.59% | -26.01% | -41.08% | -62.40% | -55.96% |
| Income Before Tax | -4.51% | -32.11% | -52.16% | -69.33% | -56.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.51% | -32.11% | -52.39% | -69.33% | -56.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.51% | -32.11% | -52.39% | -69.33% | -56.15% |
| EBIT | -2.59% | -26.01% | -41.08% | -62.40% | -55.96% |
| EBITDA | -2.52% | -26.01% | -41.21% | -62.68% | -56.23% |
| EPS Basic | 7.14% | -18.15% | -46.61% | -43.94% | -31.54% |
| Normalized Basic EPS | 7.14% | -18.15% | -46.41% | -43.95% | -31.55% |
| EPS Diluted | 7.14% | -18.15% | -46.61% | -43.94% | -31.54% |
| Normalized Diluted EPS | 7.14% | -18.15% | -46.41% | -43.95% | -31.55% |
| Average Basic Shares Outstanding | 12.55% | 11.81% | 3.94% | 17.63% | 18.71% |
| Average Diluted Shares Outstanding | 12.55% | 11.81% | 3.94% | 17.63% | 18.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |